Viremic HIV controllers exhibit high plasmacytoid dendritic cell-reactive opsonophagocytic IgG antibody responses against HIV-1 p24 associated with greater antibody isotype diversification

Journal of Immunology

Volumn 194, Issue 11, 2015, Pages 5320-5328

  Tjiam, M Christian ^a   Taylor, James P A ^a,g   Morshidi, Mazmah A ^a   Sariputra, Lucy ^a   Burrows, Sally ^c   Martin, Jeffrey N ^d   Deeks, Steven G ^e   Tan, Dino B A ^c,f   Lee, Silvia ^a,b   Fernandez, Sonia ^a   French, Martyn A ^a,b  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b ROYAL PERTH HOSPITAL   (Australia)

^c UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f Lung Institute of Western Australia   (Australia)

^g CURTIN UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN P24; FC RECEPTOR IIA; FC RECEPTOR IIB; GLYCOPROTEIN GP 140; HUMAN IMMUNODEFICIENCY VIRUS 1 ANTIGEN P24; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN G1 ANTIBODY; IMMUNOGLOBULIN G2 ANTIBODY; UNCLASSIFIED DRUG; VIRUS RNA; FC RECEPTOR; GAG PROTEIN; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; IMMUNOGLOBULIN G;

ADULT; AGED; ANTIBODY AND IMMUNOGLOBULIN STRUCTURE, FUNCTION AND PRODUCTION; ANTIBODY ISOTYPE DIVERSIFICATION; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ARTICLE; BINDING AFFINITY; CD4 LYMPHOCYTE COUNT; COMPARATIVE STUDY; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; IMMUNOREACTIVITY; INFECTION CONTROL; MAJOR CLINICAL STUDY; MALE; MOLECULAR DYNAMICS; OPSONIZATION; OPSONOPHAGOCYTIC ANTIBODY RESPONSE; PHAGOCYTOSIS; PLASMACYTOID DENDRITIC CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; VIREMIA; VIREMIC HIV CONTROLLER; VIRUS LOAD; VIRUS REPLICATION; VIRUS TITRATION; BLOOD; CD4+ T LYMPHOCYTE; CELL LINE; DENDRITIC CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; VIROLOGY;

AIDS VACCINES; CD4 LYMPHOCYTE COUNT; CD4-POSITIVE T-LYMPHOCYTES; CELL LINE; DENDRITIC CELLS; HIV ANTIBODIES; HIV CORE PROTEIN P24; HIV INFECTIONS; HIV-1; HUMANS; IMMUNOGLOBULIN G; PHAGOCYTOSIS; RECEPTORS, IGG; RNA, VIRAL; VIREMIA;

EID: 84929631097     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1402918     Document Type: Article

References (57)

1. Deeks, S. G. 2011. HIV infection, inflammation, immunosenescence, and aging. Annu. Rev. Med. 62: 141-155.
2. Deeks, S. G., B. Autran, B. Berkhout, M. Benkirane, S. Cairns, N. Chomont, T.-W. Chun, M. Churchill, M. Di Mascio, C. Katlama, et al; International AIDS Society Scientific Working Group on HIV Cure. 2012. Towards an HIV cure: a global scientific strategy. Nat. Rev. Immunol. 12: 607-614.
3. Archin, N. M., A. L. Liberty, A. D. Kashuba, S. K. Choudhary, J. D. Kuruc, A. M. Crooks, D. C. Parker, E. M. Anderson, M. F. Kearney, M. C. Strain, et al. 2012. Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy. Nature 487: 482-485.
4. Shan, L., K. Deng, N. S. Shroff, C. M. Durand, S. A. Rabi, H.-C. Yang, H. Zhang, J. B. Margolick, J. N. Blankson, and R. F. Siliciano. 2012. Stimulation of HIV-1-specific cytolytic T lymphocytes facilitates elimination of latent viral reservoir after virus reactivation. Immunity 36: 491-501.
5. Emu, B., E. Sinclair, H. Hatano, A. Ferre, B. Shacklett, J. N. Martin, J. M. McCune, and S. G. Deeks. 2008. HLA class I-restricted T-cell responses may contribute to the control of human immunodeficiency virus infection, but such responses are not always necessary for long-term virus control. J. Virol. 82: 5398-5407.
6. Pace, M. J., E. H. Graf, L. M. Agosto, A. M. Mexas, F. Male, T. Brady, F. D. Bushman, and U. O'Doherty. 2012. Directly infected resting CD4+T cells can produce HIV Gag without spreading infection in a model of HIV latency. PLoS Pathog. 8: e1002818.
7. Graf, E. H., M. J. Pace, B. A. Peterson, L. J. Lynch, S. B. Chukwulebe, A. M. Mexas, F. Shaheen, J. N. Martin, S. G. Deeks, M. Connors, et al. 2013. Gag-positive reservoir cells are susceptible to HIV-specific cytotoxic T lymphocyte mediated clearance in vitro and can be detected in vivo [corrected]. PLoS ONE 8: e71879.
8. Cohen, J. 2013. AIDS research. More woes for struggling HIV vaccine field. Science 340: 667.
9. Barouch, D. H., J. B. Whitney, B. Moldt, F. Klein, T. Y. Oliveira, J. Liu, K. E. Stephenson, H.-W. Chang, K. Shekhar, S. Gupta, et al. 2013. Therapeutic efficacy of potent neutralizing HIV-1-specific monoclonal antibodies in SHIVinfected rhesus monkeys. Nature 503: 224-228.
10. Shingai, M., Y. Nishimura, F. Klein, H. Mouquet, O. K. Donau, R. Plishka, A. Buckler-White, M. Seaman, M. Piatak, Jr., J. D. Lifson, et al. 2013. Antibodymediated immunotherapy of macaques chronically infected with SHIV suppresses viraemia. Nature 503: 277-280.
11. French, M. A., L. N. Abudulai, and S. Fernandez. 2013. Isotype diversification of IgG antibodies to HIV Gag proteins as a therapeutic vaccination strategy for HIV infection. Vaccines 1: 328-342.
12. Sandler, N. G., S. E. Bosinger, J. D. Estes, R. T. Zhu, G. K. Tharp, E. Boritz, D. Levin, S. Wijeyesinghe, K. N. Makamdop, G. Q. del Prete, et al. 2014. Type I interferon responses in rhesus macaques prevent SIV infection and slow disease progression. Nature 511: 601-605.
13. Azzoni, L., A. S. Foulkes, E. Papasavvas, A. M. Mexas, K. M. Lynn, K. Mounzer, P. Tebas, J. M. Jacobson, I. Frank, M. P. Busch, et al. 2013. Pegylated interferon alfa-2a monotherapy results in suppression of HIV type 1 replication and decreased cell-associated HIV DNA integration. J. Infect. Dis. 207: 213-222.
14. Sun, H., M. J. Buzon, A. Shaw, R. K. Berg, X. G. Yu, S. Ferrando-Martinez, M. Leal, E. Ruiz-Mateos, and M. Lichterfeld. 2014. Hepatitis C therapy with interferon-a and ribavirin reduces CD4 T-cell-associated HIV-1 DNA in HIV-1/ hepatitis C virus-coinfected patients. J. Infect. Dis. 209: 1315-1320.
15. Tomescu, C., F.-M. Duh, R. Hoh, A. Viviani, K. Harvill, M. P. Martin, M. Carrington, S. G. Deeks, and L. J. Montaner. 2012. Impact of protective killer inhibitory receptor/human leukocyte antigen genotypes on natural killer cell and T-cell function in HIV-1-infected controllers. AIDS 26: 1869-1878.
16. Barblu, L., K. Machmach, C. Gras, J.-F. Delfraissy, F. Boufassa, M. Leal, E. Ruiz-Mateos, O. Lambotte, and J.-P. Herbeuval, ANRS EP36 HIV Controllers Study Group. 2012. Plasmacytoid dendritic cells (pDCs) from HIV controllers produce interferon-a and differentiate into functional killer pDCs under HIV activation. J. Infect. Dis. 206: 790-801.
17. Machmach, K., M. Leal, C. Gras, P. Viciana, M. Genebat, E. Franco, F. Boufassa, O. Lambotte, J. P. Herbeuval, and E. Ruiz-Mateos. 2012. Plasmacytoid dendritic cells reduce HIV production in elite controllers. J. Virol. 86: 4245-4252.
18. Wang, J. P., D. R. Asher, M. Chan, E. A. Kurt-Jones, and R. W. Finberg. 2007. Cutting edge: antibody-mediated TLR7-dependent recognition of viral RNA. J. Immunol. 178: 3363-3367.
19. Lannes, N., S. Python, and A. Summerfield. 2012. Interplay of foot-and-mouth disease virus, antibodies and plasmacytoid dendritic cells: virus opsonization under non-neutralizing conditions results in enhanced interferon-alpha responses. Vet. Res. 43: 64.
20. Mikolajczyk, M. G., N. F. Concepcion, T. Wang, D. Frazier, B. Golding, C. E. Frasch, and D. E. Scott. 2004. Characterization of antibodies to capsular polysaccharide antigens of Haemophilus influenzae type b and Streptococcus pneumoniae in human immune globulin intravenous preparations. Clin. Diagn. Lab. Immunol. 11: 1158-1164.
21. Soininen, A., I. Seppälä, T. Nieminen, J. Eskola, and H. Käyhty. 1999. IgG subclass distribution of antibodies after vaccination of adults with pneumococcal conjugate vaccines. Vaccine 17: 1889-1897.
22. Jung, D.-J., J.-H. An, K. Kurokawa, Y.-C. Jung, M.-J. Kim, Y. Aoyagi, M. Matsushita, S. Takahashi, H.-S. Lee, K. Takahashi, and B. L. Lee. 2012. Specific serum Ig recognizing staphylococcal wall teichoic acid induces complement-mediated opsonophagocytosis against Staphylococcus aureus. J. Immunol. 189: 4951-4959.
23. Dillon, T. M., M. S. Ricci, C. Vezina, G. C. Flynn, Y. D. Liu, D. S. Rehder, M. Plant, B. Henkle, Y. Li, S. Deechongkit, et al. 2008. Structural and functional characterization of disulfide isoforms of the human IgG2 subclass. J. Biol. Chem. 283: 16206-16215.
24. Wypych, J., M. Li, A. Guo, Z. Zhang, T. Martinez, M. J. Allen, S. Fodor, D. N. Kelner, G. C. Flynn, Y. D. Liu, et al. 2008. Human IgG2 antibodies display disulfide-mediated structural isoforms. J. Biol. Chem. 283: 16194-16205.
25. Martinez, T., A. Guo, M. J. Allen, M. Han, D. Pace, J. Jones, R. Gillespie, R. R. Ketchem, Y. Zhang, and A. Balland. 2008. Disulfide connectivity of human immunoglobulin G2 structural isoforms. Biochemistry 47: 7496-7508.
26. Yoo, E. M., L. A. Wims, L. A. Chan, and S. L. Morrison. 2003. Human IgG2 can form covalent dimers. J. Immunol. 170: 3134-3138.
27. Yang, J., A. M. Goetze, and G. C. Flynn. 2014. Assessment of naturally occurring covalent and total dimer levels in human IgG1 and IgG2. Mol. Immunol. 58: 108-115.
28. Bruhns, P., B. Iannascoli, P. England, D. A. Mancardi, N. Fernandez, S. Jorieux, and M. Daëron. 2009. Specificity and affinity of human Fcg receptors and their polymorphic variants for human IgG subclasses. Blood 113: 3716-3725.
29. Syam, S., P. Mero, T. Pham, C. A. McIntosh, P. Bruhns, and J. W. Booth. 2010. Differential recruitment of activating and inhibitory FcgRII during phagocytosis. J. Immunol. 184: 2966-2973.
30. den Dunnen, J., L. T. Vogelpoel, T. Wypych, F. J. Muller, L. de Boer, T. W. Kuijpers, S. A. Zaat, M. L. Kapsenberg, and E. C. de Jong. 2012. IgG opsonization of bacteria promotes Th17 responses via synergy between TLRs and FcgRIIa in human dendritic cells. Blood 120: 112-121.
31. Guilliams, M., P. Bruhns, Y. Saeys, H. Hammad, and B. N. Lambrecht. 2014. The function of Fcg receptors in dendritic cells and macrophages. Nat. Rev. Immunol. 14: 94-108.
32. Hessell, A. J., L. Hangartner, M. Hunter, C. E. Havenith, F. J. Beurskens, J. M. Bakker, C. M. Lanigan, G. Landucci, D. N. Forthal, P. W. Parren, et al. 2007. Fc receptor but not complement binding is important in antibody protection against HIV. Nature 449: 101-104.
33. Ngo-Giang-Huong, N., D. Candotti, A. Goubar, B. Autran, M. Maynart, D. Sicard, J.-P. Clauvel, H. Agut, D. Costagliola, and C. Rouzioux, French Asymptomatic Long-Term Study Group. 2001. HIV type 1-specific IgG2 antibodies: markers of helper T cell type 1 response and prognostic marker of longterm nonprogression. AIDS Res. Hum. Retroviruses 17: 1435-1446.
34. Martinez, V., D. Costagliola, O. Bonduelle, N. N'go, A. Schnuriger, I. Théodorou, J.-P. Clauvel, D. Sicard, H. Agut, P. Debré, et al; Asymptomatiques à Long Terme Study Group. 2005. Combination of HIV-1-specific CD4 Th1 cell responses and IgG2 antibodies is the best predictor for persistence of long-term nonprogression. J. Infect. Dis. 191: 2053-2063.
35. French, M. A., R. J. Center, K. M. Wilson, I. Fleyfel, S. Fernandez, A. Schorcht, I. Stratov, M. Kramski, S. J. Kent, and A. D. Kelleher. 2013. Isotype-switched immunoglobulin G antibodies to HIV Gag proteins may provide alternative or additional immune responses to 'protective' human leukocyte antigen-B alleles in HIV controllers. AIDS 27: 519-528.
36. Matsumoto, K., H. Yoshikawa, T. Yasugi, S. Nakagawa, K. Kawana, S. Nozawa, H. Hoshiai, K. Shiromizu, T. Kanda, and Y. Taketani. 1999. Balance of IgG subclasses toward human papillomavirus type 16 (HPV16) L1-capsids is a possible predictor for the regression of HPV16-positive cervical intraepithelial neoplasia. Biochem. Biophys. Res. Commun. 258: 128-131.
37. Jackson, K. J., Y. Wang, and A. M. Collins. 2014. Human immunoglobulin classes and subclasses show variability in VDJ gene mutation levels. Immunol. Cell Biol. 92: 729-733.
38. Pan-Hammarström, Q., Y. Zhao, and L. Hammarström. 2007. Class switch recombination: a comparison between mouse and human. Adv. Immunol. 93: 1-61.
39. Chaperot, L., A. Blum, O. Manches, G. Lui, J. Angel, J.-P. Molens, and J. Plumas. 2006. Virus or TLR agonists induce TRAIL-mediated cytotoxic activity of plasmacytoid dendritic cells. J. Immunol. 176: 248-255.
40. Ackerman, M. E., B. Moldt, R. T. Wyatt, A.-S. Dugast, E. McAndrew, S. Tsoukas, S. Jost, C. T. Berger, G. Sciaranghella, Q. Liu, et al. 2011. A robust, high-throughput assay to determine the phagocytic activity of clinical antibody samples. J. Immunol. Methods 366: 8-19.
41. Chung, A. W., M. Ghebremichael, H. Robinson, E. Brown, I. Choi, S. Lane, A.-S. Dugast, M. K. Schoen, M. Rolland, and T. J. Suscovich. 2014. Polyfunctional Fc-effector profiles mediated by IgG subclass selection distinguish RV144 and VAX003 vaccines. Sci. Transl. Med. 6: 228ra238.
42. Binley, J. M., P. J. Klasse, Y. Cao, I. Jones, M. Markowitz, D. D. Ho, and J. P. Moore. 1997. Differential regulation of the antibody responses to Gag and Env proteins of human immunodeficiency virus type 1. J. Virol. 71: 2799-2809.
43. Deeks, S. G., J. N. Martin, E. Sinclair, J. Harris, T. B. Neilands, H. T. Maecker, E. Hagos, T. Wrin, C. J. Petropoulos, B. Bredt, and J. M. McCune. 2004. Strong cell-mediated immune responses are associated with the maintenance of lowlevel viremia in antiretroviral-treated individuals with drug-resistant human immunodeficiency virus type 1. J. Infect. Dis. 189: 312-321.
44. Alatrakchi, N., C. Duvivier, D. Costagliola, A. Samri, A. G. Marcelin, G. Kamkamidze, M. Astriti, R. Agher, V. Calvez, B. Autran, and C. Katlama. 2005. Persistent low viral load on antiretroviral therapy is associated with T cellmediated control of HIV replication. AIDS 19: 25-33.
45. Banerjee, K., P. J. Klasse, R. W. Sanders, F. Pereyra, E. Michael, M. Lu, B. D. Walker, and J. P. Moore. 2010. IgG subclass profiles in infected HIV type 1 controllers and chronic progressors and in uninfected recipients of Env vaccines. AIDS Res. Hum. Retroviruses 26: 445-458.
46. Lai, J. I., A. F. Licht, A.-S. Dugast, T. Suscovich, I. Choi, C. Bailey-Kellogg, G. Alter, and M. E. Ackerman. 2014. Divergent antibody subclass and specificity profiles but not protective HLA-B alleles are associated with variable antibody effector function among HIV-1 controllers. J. Virol. 88: 2799-2809.
47. Lamere, M. W., A. Moquin, F. E.-H. Lee, R. S. Misra, P. J. Blair, L. Haynes, T. D. Randall, F. E. Lund, and D. A. Kaminski. 2011. Regulation of antinucleoprotein IgG by systemic vaccination and its effect on influenza virus clearance. J. Virol. 85: 5027-5035.
48. LaMere, M. W., H.-T. Lam, A. Moquin, L. Haynes, F. E. Lund, T. D. Randall, and D. A. Kaminski. 2011. Contributions of antinucleoprotein IgG to heterosubtypic immunity against influenza virus. J. Immunol. 186: 4331-4339.
49. Jouvenet, N., S. M. Simon, and P. D. Bieniasz. 2009. Imaging the interaction of HIV-1 genomes and Gag during assembly of individual viral particles. Proc. Natl. Acad. Sci. USA 106: 19114-19119.
50. Chen, J., D. Grunwald, L. Sardo, A. Galli, S. Plisov, O. A. Nikolaitchik, D. Chen, S. Lockett, D. R. Larson, V. K. Pathak, and W. S. Hu. 2014. Cytoplasmic HIV-1 RNA is mainly transported by diffusion in the presence or absence of Gag protein. Proc. Natl. Acad. Sci. USA 111: E5205-E5213.
51. Li, S. S., P. B. Gilbert, G. D. Tomaras, G. Kijak, G. Ferrari, R. Thomas, C.-W. Pyo, S. Zolla-Pazner, D. Montefiori, H.-X. Liao, et al. 2014. FCGR2C polymorphisms associate with HIV-1 vaccine protection in RV144 trial. J. Clin. Invest. 124: 3879-3890.
52. Ackerman, M. E., A.-S. Dugast, E. G. McAndrew, S. Tsoukas, A. F. Licht, D. J. Irvine, and G. Alter. 2013. Enhanced phagocytic activity of HIV-specific antibodies correlates with natural production of immunoglobulins with skewed affinity for FcgR2a and FcgR2b. J. Virol. 87: 5468-5476.
53. Lambotte, O., J. Pollara, F. Boufassa, C. Moog, A. Venet, B. F. Haynes, J.-F. Delfraissy, A. Saez-Cirion, and G. Ferrari. 2013. High antibody-dependent cellular cytotoxicity responses are correlated with strong CD8 T cell viral suppressive activity but not with B57 status in HIV-1 elite controllers. PLoS ONE 8: e74855.
54. Forthal, D. N., G. Landucci, J. Bream, L. P. Jacobson, T. B. Phan, and B. Montoya. 2007. FcgRIIa genotype predicts progression of HIV infection. J. Immunol. 179: 7916-7923.
55. French, M. A., S. Tanaskovic, M. G. Law, A. Lim, S. Fernandez, L. D. Ward, A. D. Kelleher, and S. Emery. 2010. Vaccine-induced IgG2 anti-HIV p24 is associated with control of HIV in patients with a "high-affinity" FcgRIIa genotype. AIDS 24: 1983-1990.
56. Forthal, D. N., G. Landucci, H. Ding, J. C. Kappes, A. Wang, I. Thung, and T. Phan. 2011. IgG2 inhibits HIV-1 internalization by monocytes, and IgG subclass binding is affected by gp120 glycosylation. AIDS 25: 2099-2104.
57. Stahl, D., andW. Sibrowski. 2006. IgG2 containing IgM-IgG immune complexes predominate in normal human plasma, but not in plasma of patients with warm autoimmune haemolytic anaemia. Eur. J. Haematol. 77: 191-202.